Sign in
CompletedPhase 3

Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection

Key facts

Who runs it
TenNor Therapeutics (Suzhou) Limited
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
700 people enrolled
Started
18 May 2023
Ended
26 Mar 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Rifasutenizol capsules
  • Rabeprazole sodium enteric-coated tablets
  • Amoxicillin Capsules
  • Clarithromycin placebo tablets
  • Bismuth potassium citrate placebo capsules
  • Clarithromycin tablets
  • Bismuth potassium citrate capsules
  • Rifasutenizol placebo capsules
Record updated
17 August 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Voluntarily sign the informed consent form
  • Age 18-65 years (inclusive), male or female
  • The result of 13C-UBT is positive (≥ 4 Delta Over Baseline), and the infection of H. pylori are confirmed by gastroscopic biopsy histology
  • Subjects agree to refrain from taking any antibiotics or traditional Chinese medicines with antibacterial effect, bismuth, and antacids (such as proton pump inhibitor, H2 receptor blocker, P-CAB) other than the study drugs during the Screening Period until the end of the study (Visit 5, i.e., Efficacy Evaluation Visit)
  • Subjects and their heterosexual partners must agree to have no pregnancy plan and voluntarily take effective contraceptive measures during the trial and for at least 6 months after the end of the study medication
  • Willing to follow and able to complete all trial procedures

Who cannot take part

  • History of neoplasm malignant within 5 years prior to screening, with the exception of basal cell carcinoma or carcinoma cervix in situ treated without evidence of recurrence
  • History of substance abuse or drug use within 5 years prior to screening
  • Alcohol abuse or a history of alcohol abuse within 5 years prior to screening (average weekly consumption of ≥ 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine/Chinese rice wine/rice wine)
  • Anticoagulant therapy or long-term treatment with nonsteroidal anti-inflammatory drugs
  • Treatment with any other investigational new drugs within 4 weeks prior to the Screening Period
  • Any prohibited medications or non-drug therapies as specified in the protocol (see Section 10.3)
  • History of H. pylori eradication therapy (including participation in other clinical trials for H. pylori eradication)
  • Subjects with confirmed tuberculosis (TB) or Mycobacterium avium complex (MAC) infection or a history of TB or MAC infection
  • History of dysphagia or any gastrointestinal disorder affecting drug absorption
  • History of obstruction pyloric; or excessive gastric acid secretion (such as Zollinger-Ellison syndrome)
  • History of gastric cancer
  • History of esophageal or gastric surgery, except for simple repair of the perforated ulcer
  • Presence of active gastric and/or duodenal ulcer
  • Test positive for hepatitis B surface antigen, hepatitis C antibody, AIDS antibody, or microspironema pallidum antibody
  • Other conditions considered inappropriate to participate in this study by the Investigator, e.g., the subject has a history of severe central nervous system, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine, or hematological diseases, or has clinical manifestations of these diseases
  • Allergy to any of the study drugs (rabeprazole, amoxicillin, clarithromycin, bismuth potassium citrate), allergic constitution (multiple drug and food allergies); or any contraindication to the use of rifamycin, nitroimidazoles or study drugs
  • White blood cell count or neutrophil count below the lower limit of normal range
  • Anemia (hemoglobin < 90 g/L)
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, or serum creatinine above the upper limit of normal range
  • Abnormal ECG with clinical significance
  • Female subjects who are pregnant, lactating, or have a positive urine pregnancy result during the Screening Period
  • Inability to communicate with the Investigator and to comply with the study requirements

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.

The 2 groups in the trial

  • Test GroupTreatment being tested

    Rifasutenizol capsules 400 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Amoxicillin capsules 1 g + Bismuth potassium citrate placebo capsules + Clarithromycin placebo tablets, twice daily (BID) for 14 days

    Treatment: Rifasutenizol capsules, Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules, Clarithromycin placebo tablets, and Bismuth potassium citrate placebo capsules

  • Control GroupExisting treatment, for comparison

    Amoxicillin capsules 1 g + Clarithromycin tablets 500 mg + Rabeprazole sodium enteric-coated tablets 20 mg + Bismuth potassium citrate capsules 240 mg + Rifasutenizol placebo capsules, BID for 14 days

    Treatment: Rabeprazole sodium enteric-coated tablets, Amoxicillin Capsules, Clarithromycin tablets, Bismuth potassium citrate capsules, and Rifasutenizol placebo capsules

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection
Publications
Record updated
17 August 2025